Although metastatic breast cancer is unlikely to be cured, meaningful improvements in survival have been seen, coincident with the introduction of newer systemic therapies [1-3]. Median overall survival (OS) approaches two years, with a range from a few months to many years .
The selection of a therapeutic strategy depends upon both tumor biology and clinical factors, with the goal being a tailored approach. Although a subset of patients with oligometastatic disease may benefit from an intensified locoregional approach, most patients with metastatic breast cancer receive systemic medical therapy consisting of chemotherapy, endocrine therapy, and/or biologic therapies, and supportive care measures [5,6].
General principles of management of metastatic breast cancer are presented here. Details of single agent and combination chemotherapy, endocrine therapy, biologic therapy, and how to select among them, as well as locoregional approaches, osteoclast inhibitors (bisphosphonates and receptor activator of nuclear factor kappa-B [RANK] ligand inhibitors), and supportive care, are discussed separately.
●(See "Treatment approach to metastatic hormone receptor-positive breast cancer: Endocrine therapy".)
●(See "Systemic treatment of metastatic breast cancer in women: Chemotherapy".)